Table 6.
Trials in loco-regional and/or metastatic unresectable disease with targeted therapies.
| Drug | Phase (N) | Patient Characteristics | RR | DC | mDoR | mPFS | mOS | Ref. |
|---|---|---|---|---|---|---|---|---|
| Erlotinib | II (39) | PS 0–2 Median age 68 y |
10% (no CR) |
72% | 7.2 mo | 4.7 mo | 13 mo | [64] |
| Gefitinib | II (40) | PS 0–2 Median age 67 y |
16% (no CR) |
51% | 31.4 mo | 3.8 mo | 12.9 mo | [65] |
| Cetuximab | II (36) | PS 0–2 Strong/moderate EGFR expression Median age 79 y |
28% (6% CR) |
68% | 6.8 mo | 4.1 mo | NR | [66] |
| Panitumumab | II (16) | PS 0–2 Median age 68 y |
31% (12% CR) |
69% | 6 mo | 8 mo | 11 mo | [67] |
CR, complete response; DC, disease control; DoR, duration of response; mo, months; m, median; N, patient number; NR, not reached; OS, overall survival; PFS, progression-free survival; PS, performance status; RR, response rate; y, years.